“…The analgesic properties of morphine, 206-280 its use in anaesthesia, 281-284 and its metabolism 285,286 and pharmacokinetics 287-292 have been studied, as have the effects of the alkaloid on behaviour, 293-329 on the brain, 330-347 on immune responses, [348][349][350][351][352][353][354][355][356][357][358] on the cardio-vascular system, 359-361 on neurones, 362-366 on locomotion, 367-370 on the gastro-intestinal tract, 371-375 on gene expression, 376-381 on the adrenal 382 and thymus 383 glands, on tumour growth, 384-387 on the replication of HIV, 388 on inflammation, 389-391 on platelet aggregation, 392 on respiration, 393 on nerve transmission, 394 on reflex muscle activity, 395,396 on the sphincter of Oddy, 397 on susceptibility to epileptic seizures, 398,399 on memory, 400 on intake of ethanol, 401 on the release of dopamine, 402-405 of serotonin, 406,407 of adenosine, 408 of synaptosomal ATPase, 409 of corticosterone 410 and of preprodynorphin, 411 on dopamine 412 and oestrogen 413 receptors, on G-protein function, 414 on the transport of glutamate, 415,416 on the metabolism of glucose, 417 on the degradation of endothelin-l 418 and on the effects of endomorphins 1 and 2. 419 The morphine antagonist actions of naloxone have been studied, [420][421][422][423][424][425][426][427][428] as have the effects of this compound on behaviour, 429-432 on the heart, 433 on the gastro-intestinal tract, 434 on pain, 435,436 on the intake of food 437,438 and of ethanol, 439,440 on neurones, 441 on calcium channels, 442 on the release of dopamine, 443 of oxytocin 444 and of the natriuretic peptide,…”